In Vivo Viral based CAR-T Cell Development Services

By leveraging the transformative potential of in vivo CAR-T technology, Creative Biolabs offers comprehensive In vivo Viral-based CAR-T Development Services aimed at overcoming the major limitations of conventional ex vivo approaches. Our platform is designed to bypass the lengthy, costly, and logistically complex manufacturing processes by directly engineering patient T cells in vivo using targeted lentiviral and AAV delivery systems. This enables sustained CAR expression, enhanced T-cell persistence, and reduced immunotoxicity, accelerating therapeutic development while improving clinical accessibility and scalability for next-generation cell therapies.

Introduction

The ex vivo CAR-T relies on isolating T cells from patients or healthy donors, followed by genetic modification and expansion outside the body before reinfusion, a process that is complex, time-consuming, and costly. In contrast, the in vivo strategy employs systemic delivery vehicles to directly reprogram circulating T cells within the patient, thereby bypassing extensive ex vivo manipulation, streamlining the production workflow, and significantly lowering the barriers to therapeutic access. Viral vector-based platforms, particularly those utilizing lentivirus and adeno-associated virus, have emerged as a major focus of current research due to their high transduction efficiency and sustained CAR expression.

Fig.1 Comparative analysis: ex vivo and in vivo CAR-T generation.¹

In vivo Viral-based CAR-T Development Services at Creative Biolabs

Creative Biolabs' In vivo Viral-based CAR-T Development Services genetically engineers specific T cell subsets directly within the patient to generate functional CAR-T cells in situ. Our strengths lie in integrating clinically validated CAR designs, highly specific viral targeting systems, and comprehensive in vivo efficacy and safety assessment platforms. Together, these capabilities establish a more efficient, safe, and scalable pathway for next-generation CAR-T therapy development.

Service Packages

We provide two distinct, cutting-edge delivery approaches, AAV and Lentivirus vector technologies, designed to enable efficient and durable in situ engineering of patient T cells. Each system offers unique advantages in terms of safety, persistence, and manufacturing scalability.

• In vivo CAR-T Development with AAV Vector Technology

This service utilizes recombinant AAV vectors for the targeted delivery of CAR constructs directly into circulating T cells in vivo. Its advantages include high transduction efficiency in non-dividing cells, low immunogenicity, and sustained episomal expression, enabling durable CAR-T responses with reduced manufacturing time and complexity.

• In vivo CAR-T Development with Lentivirus Technology

Through engineered lentiviral vectors pseudotyped with T cell-targeting ligands, we achieve stable genomic integration and persistent CAR expression in vivo. This approach offers high transduction efficiency, scalability, and the ability to maintain long-term T cell functionality, providing a robust platform for "off-the-shelf" in vivo CAR-T therapy development.

Our Service Process

Required starting materials:

• Target Antigen Information: The specific cell surface target for the CAR-T therapy.
• CAR Genetic Sequence: The detailed DNA or mRNA sequence encoding the CAR, including the signal peptide, scFv, hinge, transmembrane, and intracellular costimulatory domains.
• Target Cell Phenotype Data: Any available in vitro or in vivo data regarding the T cell subset targeted and their functional characteristics in the disease model.

Key Steps:

Final Deliverables:

• Validated Viral Vector Stock: A master/working stock of the optimized, T cell-retargeted viral vector.
• Comprehensive Safety and Biodistribution Report: Detailed in vivo data on T cell specificity, CAR expression levels, persistence, and off-target transduction results.
• CAR Optimization and Persistence Data: Functional data comparing the engineered CAR's performance against benchmark designs, providing rationale for the chosen costimulatory domain combination.

Key Advantages

• One-Stop In vivo Platform: We provide an integrated service that bypasses the entire ex vivo manufacturing bottleneck, from genetic design and vector production to comprehensive in vivo validation studies.
• Proprietary T Cell Retargeting: Utilize our advanced, engineered viral envelopes for superior cellular tropism to specific T cell subsets, ensuring high-efficiency transduction only in the required immune cell population.
• Customizable CAR Optimization: We offer tailored services to select and integrate optimal costimulatory domains, guaranteeing superior T cell expansion and long-term persistence based on your specific therapeutic goals and disease models.

FAQ

Why Choose Us?

We provide an advanced viral delivery platform specifically engineered to generate CAR-T cells directly within the patient. Our expertise integrates clinically validated CAR designs with targeted viral envelope engineering and proprietary technology to ensure precise T cell transduction, enhanced functional persistence, and superior safety. This approach eliminates ex vivo manufacturing, offering a scalable and efficient path to next-generation cell therapies.

Related Services

In the evolving field of in vivo CAR-T engineering, we are dedicated to pioneering novel platforms that significantly improve therapeutic efficacy and accessibility in oncology.

• In vivo IVT mRNA-based CAR-T Cell Engineering Service

This service leverages in vitro-transcribed (IVT) mRNA encapsulated in advanced lipid nanoparticles (LNPs) to enable transient yet potent CAR expression directly within circulating T cells in vivo, allowing for rapid, dose-tunable CAR-T generation without genomic integration and reducing long-term safety risks.

• In vivo Circular RNA-based CAR-T Cell Engineering Service

Utilizing engineered circular RNA (circRNA) delivered via targeted non-viral carriers, this platform facilitates extended CAR protein expression compared to linear mRNA due to its inherent resistance to exonucleases. The service offers enhanced translational durability and stability in vivo, supporting sustained T cell activity while circumventing the need for viral vectors or repeated dosing.

How to contact us?

To explore tailored solutions for your project, obtain a customized workflow proposal, or learn more about our proprietary platforms, please reach out to our scientific team for a detailed consultation.

Reference

1. Pinto, E et al. "From ex vivo to in vivo chimeric antigen T cells manufacturing: new horizons for CAR T-cell based therapy." Journal of translational medicine vol. 23,1 10. Distributed under Open Access License CC BY 4.0, without modification. https://doi.org/10.1186/s12967-024-06052-3.